Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Abionyx Pharma SA is a new-generation biotechnology company focused on discovering and developing innovative therapies for patients lacking effective treatments, particularly in renal and ophthalmological diseases. It specializes in HDL (High Density Lipoprotein) therapies, leveraging advanced lipoprotein particles to address unmet medical needs. Key drug candidates include CER-001, a recombinant apoA-I based HDL mimetic designed to replicate pre-beta HDL properties for treating post-acute coronary syndrome and familial hypoalphalipoproteinemia; CER-002, a peroxisome proliferator-activated receptor delta agonist targeting cardiovascular and metabolic disorders; and CER-209, aimed at metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). Formerly known as Cerenis Therapeutics Holding SA, the company rebranded in August 2019. Founded in 2005 and headquartered in Balma, France, Abionyx Pharma SA collaborates with research, medical, and biopharmaceutical partners to advance targeted drug delivery using novel HDL vectors, contributing significantly to the biotech sector's efforts in cardiovascular, metabolic, and rare disease innovation.
€1.97
+€0.08 (+4.24%)
EOD Aug 7, 2026
The business is unprofitable at the operating level (-133.60% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 10.7% YoY. Margins deteriorated 38.6pp alongside, both lines moving the wrong way.
ROIC dropped from -31.65% to -46.14%, capital efficiency is deteriorating. Negative free cash flow of -€3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€4M
▼ -10.7% YoY
Net Income (TTM)
-€6M
▼ -26.7% YoY
Op. Margin
-133.60%
▼ -38.6pp YoY
ROIC
-46.14%
▼ -14.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€3M
▲ +14.4% YoY
Op. Cash Flow (TTM)
-€3M
▲ +18.5% YoY
Net Debt
€284K
Cash & Equiv.
€4M
3Y CAGR: -8.2%
Continue Research
Abionyx Pharma SA (ABNX.XPAR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Abionyx Pharma SA scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Abionyx Pharma SA scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -133.6% operating margin and a -46.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ABNX.XPAR's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.